OncoCyte Corp.

How big is OncoCyte Corp.?

As of Jun 18, OncoCyte Corp. has a market capitalization of 91.52 million, with net sales of 3.85 million and a net profit of -58.20 million over the last four quarters. As of Dec 24, shareholder's funds are at -12.27 million and total assets are 35.08 million.

As of Jun 18, OncoCyte Corp. has a market capitalization of 91.52 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 3.85 million, while the sum of net profit for the same period is -58.20 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -12.27 million and total assets at 35.08 million.

What does OncoCyte Corp. do?

OncoCyte Corporation is a development-stage biotechnology company specializing in molecular cancer diagnostics, with a market cap of $91.52 million and recent net sales of $2 million, but a net loss of $7 million. The company has no dividend yield and significant negative return on equity.

Overview: <BR>OncoCyte Corporation is a development-stage biotechnology company focused on molecular cancer diagnostics within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 91.52 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.90 <BR>Return on Equity: -225.22% <BR>Price to Book: 8.96<BR><BR>Contact Details: <BR>Address: 15 CUSHING, IRVINE CA: 92618 <BR>Tel: ['1 949 4097600', '1 646 5976979'] <BR>Fax: 1 510 5213389 <BR>Website: http://www.oncocyte.com/

Should I buy, sell or hold OncoCyte Corp.?

Who are in the management team of OncoCyte Corp.?

As of March 2022, the management team of OncoCyte Corp. includes Mr. Cavan Redmond (Independent Chairman), Mr. Ronald Andrews (President and CEO), and Independent Directors Mr. Andrew Arno, Ms. Melinda Griffith, and Dr. Andrew Last. They oversee the company's strategic direction and operations.

As of March 2022, the management team of OncoCyte Corp. includes the following individuals:<BR><BR>- Mr. Cavan Redmond, who serves as the Independent Chairman of the Board.<BR>- Mr. Ronald Andrews, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Andrew Arno, who is an Independent Director.<BR>- Ms. Melinda Griffith, who is also an Independent Director.<BR>- Dr. Andrew Last, who is an Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is OncoCyte Corp. overvalued or undervalued?

As of March 24, 2025, OncoCyte Corp. is considered a risky investment due to its high Price to Book Value of 8.31 and negative EV to EBIT of -2.37, despite a strong year-to-date return of 41.60%, overshadowed by an 87.96% decline over the past five years.

As of 24 March 2025, the valuation grade for OncoCyte Corp. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 8.31, a negative EV to EBIT of -2.37, and an EV to Sales ratio of 14.39, which suggests that the market is pricing the stock at a premium despite its losses. <BR><BR>In comparison to its peer, Cyclo Therapeutics, Inc., which has an EV to EBITDA of -1.3007, OncoCyte's metrics indicate a less favorable position. Additionally, the company's recent stock performance shows a 41.60% year-to-date return, significantly outperforming the S&P 500's 12.22%, but this is overshadowed by a drastic decline of 87.96% over the past five years, highlighting the volatility and risk associated with the stock.

Is OncoCyte Corp. technically bullish or bearish?

As of September 8, 2025, OncoCyte Corp. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but with significantly negative long-term returns.

As of 8 September 2025, the technical trend for OncoCyte Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD readings are mildly bullish. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames, suggesting some upward potential. However, KST and OBV show mixed signals, with weekly KST bearish and monthly KST mildly bullish, while OBV is mildly bullish weekly and mildly bearish monthly. <BR><BR>In terms of performance, OncoCyte has outperformed the S&P 500 over the past week and month, with returns of 5.97% and 26.22% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns over 1 year and beyond are significantly negative compared to the benchmark.